)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genfit
Genfit (GNFT) investor relations material
Genfit Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary5 Nov, 2026
Executive summary
Cash of €95.6m at September 30, 2026; expected to fund operations beyond 2028, with royalties, milestones and diagnostic revenue expected to support longer-term funding and profitability.
Nine-month revenue was €36.3m, primarily royalties on Iqirvo sales, up 188% YoY; three Phase 2 studies across ACLF and CCA are advancing toward 2027 readouts.
Financial highlights
Cash and cash equivalents were €95.6m at September 30, 2026, versus €113.8m at June 30, 2026 and €101.1m at December 31, 2025.
Nine-month 2026 revenue totaled €36,433 thousand: royalties €36,308 thousand, milestone revenue nil and other revenue €125 thousand; nine-month 2025 total was €39,233 thousand.
Royalty revenue rose 188% YoY, reflecting accelerating U.S. sales and performance in Europe and other markets.
Outlook and guidance
Existing cash is expected to cover operating expenses and capex beyond 2028; longer-term funding assumptions include continued Iqirvo growth, significant Ipsen milestones, controlled spending, diagnostic revenue and potential use of the final royalty-financing installment.
PBC label-update submission is underway following positive ELSPIRE results; ELASCOPE PSC data are expected around 2031.
Nangibotide ACLF Phase 2 is expected to start by year-end 2026, with data targeted for H2 2027; NTZ proof-of-concept data are expected mid-2027.
GNS561 Phase 2 in KRAS-mutated CCA is on track to start by year-end 2026, with readout targeted for H2 2027; additional Phase 1b data are expected by year-end.
An industrial strategy for NIS technology-based IVD development and commercialization is expected toward year-end; subject to development, approval, partner execution and adoption, launch could begin from 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genfit
- Strong royalty growth, pipeline progress, and a net loss of €26.1M in H1 2026.GNFT
Q2 2026 - Commercial success in PBC, diagnostic advances in MASH, and a strong pipeline drive future growth.GNFTH.C. Wainwright 28th Annual Global Investment Conference presentation
- Cash position strengthened by royalty financing, with Q1 revenue growth from IqirvoⓇ royalties.GNFTQ1 2025
- NIS2+ enables scalable MASH diagnosis and monitoring, unlocking a $1.5B market opportunity.GNFTKOL event
- Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics.GNFTCorporate presentation
- Q1 2026 revenue up 243% to €9.6M, with strong cash and major clinical milestones reached.GNFTQ1 2026 TU
- Net loss of €10.0 million in H1 2025, cash runway extended beyond 2028 after VS-01 discontinuation.GNFTQ2 2025
- FDA approval and U.S. launch of Iqirvo® drove record profit, revenue, and strong cash outlook.GNFTQ2 2024
- GENFIT achieved profitability and secured major financing, fueling pipeline progress and commercial growth.GNFTQ4 2024
Next Genfit earnings date
Q4 20261 Apr, 2027
Genfit
Next Genfit earnings date
Q4 20261 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Genfit S.A. is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions in the areas of liver-related diseases and metabolic disorders. The company specializes in creating proprietary drug candidates and biomarkers to address unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. Genfit's portfolio includes both therapeutic and diagnostic assets aimed at improving patient outcomes through targeted treatment strategies and precision medicine. The company is headquartered in Loos, France, and its shares are listed on the Euronext Paris.